A good diagnostic, drug, device or therapy may not win money from a traditional investor or in a traditional way this year. Biomedical entrepreneurs and their advisers are still getting deals done, but they’re smaller deals and may include several investors instead of one, or the deals may involve government grant programs.

The Ghannoum Law Firm focuses almost exclusively on transactions and intellectual property for the life-science industry. The businesses relies on a virtual workforce and unique compensation method to provide lower costs, and its founder thinks the medical industry has grown enough to support a medically focused firm.